Inventera Receives Preliminary Approval for KOSDAQ Listing Review

Inventera, a company specializing in the development of nanomedicines, announced on December 26 that it has received preliminary approval for KOSDAQ listing review from the Korea Exchange. With recent development achievements, such as its lead pipeline INV-002 being selected as an excellent project by the Korea Drug Development Fund (KDDF), the company's core goal of pursuing an initial public offering (IPO) this year is also becoming more tangible.

Inventera plans to complete its KOSDAQ listing in the first half of 2026 after submitting a securities registration statement to the Financial Supervisory Service and conducting demand forecasting for institutional investors as part of the public offering process. The lead underwriters are NH Investment & Securities and Eugene Investment & Securities.

Currently, Inventera is conducting a domestic Phase 3 clinical trial for its lead pipeline product, the musculoskeletal nano-MRI contrast agent INV-002. The company plans to complete Phase 3 dosing by early next year and then proceed with filing for product approval. To this end, it is undergoing a preliminary review by the Ministry of Food and Drug Safety.

Development of follow-up pipelines is also underway. The lymphatic nano-MRI contrast agent INV-001 is at the Phase 2a clinical trial stage. The company is also developing INV-003, an oral nano-MRI contrast agent for pancreatobiliary diseases. Inventera recently announced that INV-003 has been selected as a KDDF project, and a research agreement has been signed. INV-003 is a next-generation nano-MRI contrast agent for the precise diagnosis of pancreatobiliary diseases such as pancreatic cancer, bile duct cancer, and pancreatic cysts. Based on this project, the company plans to accelerate clinical entry for INV-003 next year.

On the commercialization front, Inventera has signed an exclusive sales agreement for its nano-MRI contrast agent new drug with Dongkook Lifescience, the leading contrast agent distributor in Korea. Under the agreement, Dongkook Lifescience has secured exclusive rights for domestic production, marketing, sales, and distribution of the product, as well as export rights to overseas markets such as Southeast Asia.

The two companies have continued close business collaboration since the contract signing and are ramping up commercialization preparations, including pre-marketing activities, in line with the INV-002 Phase 3 clinical trial timeline. At the same time, Inventera is accelerating efforts to pursue global license-out (L/O) deals with international pharmaceutical and medical imaging companies, raising expectations for increased business visibility after the listing.

Shin Taehyun, CEO of Inventera, said, "Passing the preliminary listing review is an official recognition of our nano-drug delivery platform, nano-MRI contrast agent technology, and business potential. We will proceed with the remaining listing procedures without delay and leap forward as a global nanomedicine specialist."

Yoo Taesook, Chief Business Officer of Inventera, stated, "Through domestic and international clinical trials, we have validated our business potential in the domestic market and verified our readiness for the global regulatory environment, so our overseas market entry strategies for the pipeline are also becoming more concrete."